You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CASPOFUNGIN ACETATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Caspofungin Acetate, and when can generic versions of Caspofungin Acetate launch?

Caspofungin Acetate is a drug marketed by Areva Pharms, Cipla, Fresenius Kabi Usa, Gland, Hengrui Pharma, Norvium Bioscience, and Xellia Pharms Aps. and is included in seven NDAs. There is one patent protecting this drug.

This drug has fourteen patent family members in fourteen countries.

The generic ingredient in CASPOFUNGIN ACETATE is caspofungin acetate. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Caspofungin Acetate

A generic version of CASPOFUNGIN ACETATE was approved as caspofungin acetate by FRESENIUS KABI USA on December 30th, 2016.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CASPOFUNGIN ACETATE?
  • What are the global sales for CASPOFUNGIN ACETATE?
  • What is Average Wholesale Price for CASPOFUNGIN ACETATE?
Drug patent expirations by year for CASPOFUNGIN ACETATE
Drug Prices for CASPOFUNGIN ACETATE

See drug prices for CASPOFUNGIN ACETATE

Recent Clinical Trials for CASPOFUNGIN ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicinePhase 4
European Organisation for Research and Treatment of Cancer - EORTCPhase 3
Children's Oncology GroupPhase 3

See all CASPOFUNGIN ACETATE clinical trials

Pharmacology for CASPOFUNGIN ACETATE
Paragraph IV (Patent) Challenges for CASPOFUNGIN ACETATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CANCIDAS for Injection caspofungin acetate 50 mg/vial and 70 mg/vial 021227 1 2009-06-26

US Patents and Regulatory Information for CASPOFUNGIN ACETATE

CASPOFUNGIN ACETATE is protected by one US patents.

Patents protecting CASPOFUNGIN ACETATE

Caspofungin acetate formulations
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Areva Pharms CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 211263-001 Oct 1, 2021 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Gland CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 207092-001 Sep 29, 2017 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cipla CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 209489-002 Jul 12, 2018 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Norvium Bioscience CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 207650-002 Sep 29, 2017 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CASPOFUNGIN ACETATE

See the table below for patents covering CASPOFUNGIN ACETATE around the world.

Country Patent Number Title Estimated Expiration
Poland 2922530 ⤷  Sign Up
European Patent Office 2922530 COMPOSITIONS D'ACÉTATE DE CASPOFUNGINE (CASPOFUNGIN ACETATE FORMULATIONS) ⤷  Sign Up
Slovenia 2922530 ⤷  Sign Up
Hungary E032392 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CASPOFUNGIN ACETATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0620232 SPC/GB02/002 United Kingdom ⤷  Sign Up A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
0620232 C300076 Netherlands ⤷  Sign Up PRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024
0620232 44/2001 Austria ⤷  Sign Up PRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024
0620232 2001/029 Ireland ⤷  Sign Up PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.